139 completed, 32 unknown, 20 recruiting, 11 terminated. 223 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 223 | Completed 139, Unknown 32, Recruiting 20, Terminated 11, Withdrawn 8, Active not recruiting 6, Not yet recruiting 6, Enrolling by invitation 1 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Antiplatelets in Psoriasis Aspirin, Clopidogrel, Placebo - Psoriasis (PsO), Psoriatic Arthritis (PsA) | Phase 4 | Not yet recruiting | NYU Langone Health | 60 | 2026-09-01 | 2026-08-05 |
| Combined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis Fractional CO2 laser assisted drug delivery, Topical Corticosteroid (TCS) - Psoriasis | Phase 4 | Not yet recruiting | Cairo University | 32 | 2026-08-15 | 2026-07-20 |
| A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative | Phase 4 | Recruiting | Janssen Research & Development, LLC | 10 | 2026-08-07 | 2026-11-03 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis Betamethasone Dipropionate 0.05% Cream, Tapinarof Cream 1% - Psoriasis (PsO) | Phase 4 | Not yet recruiting | Pakistan Institute of Medical Sciences | 120 | 2026-08-01 | 2026-06-09 |
| The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease Sodium chloride tablets, Placebo Tablets - Atopic Dermatitis (Eczema), Psoriasis | Phase 4 | Recruiting | University of California, San Francisco | 50 | 2026-07-14 | 2026-09-09 |
| Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease Deucravacitinib, Placebo - Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | University of Texas Southwestern Medical Center | 128 | 2026-06-16 | 2026-09-01 |
| Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients Secukinumab 300mg s.c., Metformin, Placebo - Psoriasis, Plaque Psoriasis | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 186 | 2026-06-01 | 2026-03-25 |
| Methotrexate Versus Apremilast for Pruritus in Psoriasis Apremilast, Methotrexate - Psoriasis, Pruritus | Phase 4 | Not yet recruiting | Zarmeen Khawar | 80 | 2026-05-14 | 2026-05-15 |
| Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial GLP-1 agonists, Nutrition Counseling - Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | Medical College of Wisconsin | 22 | 2026-05-01 | 2026-11-05 |
| Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines - Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | Instituto de Investigación Marqués de Valdecilla | 1944 | 2026-04-22 | 2026-11-10 |
| Preventing Structural Damage in Early Psoriatic Arthritis Amgevita 40Mg Solution for Injection, Methotrexate (Metoject® prefilled pen) - Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | Chinese University of Hong Kong | 108 | 2026-03-16 | 2026-03-23 |
| Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 477 | 2026-03-16 | 2026-07-20 |
| Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis Xeligekimab Injection - Palmoplantar Pustulosis (PPP) | Phase 4 | Recruiting | First Hospital of China Medical University | 10 | 2026-03-01 | 2026-03-31 |
| Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety, Methotrexate - Depression, Anxiety | Phase 4 | Completed | Cairo University | 40 | 2026-02-01 | 2026-10-05 |
| Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis Semaglutide (Rybelsus®), Placebo - Psoriasis (PsO), Obesity & Overweight | Phase 4 | Recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 62 | 2026-01-15 | 2026-02-11 |
| Comparison of Efficacy and Safety of Deucravacitinib Versus Methotrexate in the Treatment of Moderate-to-Severe Plaque Psoriasis . Participants in group B will receive Methotrexate ,10mg tablets , once weekly for 28 weeks - Psoriasis | Phase 4 | Active not recruiting | Bangladesh Medical University | 106 | 2025-11-14 | 2026-11-04 |
| REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy - Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | Sint Maartenskliniek | 200 | 2025-09-15 | 2025-09-17 |
| A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) Guselkumab - Arthritis, Psoriatic | Phase 4 | Recruiting | Johnson & Johnson Private Limited | 100 | 2025-08-12 | 2026-08-28 |
| A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers Prescreen platform, biologics treatment - Psoriasis, Psoriasis Arthritis | Phase 4 | Recruiting | Taichung Veterans General Hospital | 50 | 2025-07-29 | 2025-09-02 |
Showing 20 of 223. Sign in to see all of them.
Arthritis, Psoriatic (48) · Obesity (8) · Skin Diseases (8) · Arthritis, Rheumatoid (7) · Arthritis (6) · Cardiovascular Diseases (6) · Dermatitis, Atopic (6) · Axial Spondyloarthritis (4) · Overweight (4) · Crohn Disease (3) · Diabetes Mellitus, Type 2 (3) · Spondylitis, Ankylosing (3) · Arthritis, Juvenile (2) · Colitis, Ulcerative (2)
Skin and Connective Tissue Diseases (222) · Skin Diseases, Papulosquamous (221) · Skin Diseases (215) · Musculoskeletal Diseases (51) · Joint Diseases (49) · Bone Diseases (48) · Spinal Diseases (48) · Spondylitis (47) · Spondylarthritis (46) · Spondylarthropathies (46) · Arthritis (45) · Immune System Diseases (16) · Pathological Conditions, Signs and Symptoms (12) · Nutritional and Metabolic Diseases (11)
Etanercept (29) · Adalimumab (19) · Methotrexate (19) · secukinumab (18) · apremilast (16) · guselkumab (11) · Acitretin (9) · Infliximab (8) · betamethasone dipropionate, calcipotriol drug combination (8) · Ustekinumab (7) · risankizumab (7) · brodalumab (6) · deucravacitinib (6) · efalizumab (6) · ixekizumab (6)
Psoriasis Treatment Center of Central New Jersey (10) · Amgen (9) · University Hospital, Ghent (8) · Innovaderm Research Inc. (7) · University of California, San Francisco (7) · Novartis Pharmaceuticals (6) · Eli Lilly and Company (5) · Pfizer (5) · University of Pennsylvania (5) · Assiut University (4) · Cairo University (4) · Chinese University of Hong Kong (4) · Genentech, Inc. (4) · Icahn School of Medicine at Mount Sinai (4) · Wyeth is now a wholly owned subsidiary of Pfizer (4)
United States (90) · Germany (22) · Canada (21) · Belgium (20) · Italy (18) · Denmark (16) · Spain (16) · United Kingdom (16) · France (12) · Netherlands (11) · Poland (11) · Austria (10) · China (9) · Hungary (9) · Sweden (9)
Robert Bissonnette, MD (5) · Jo Lambert, Prof. (4) · Ivor Caro, M.D. (3) · Alison Magnotti-Nagel (2) · Boni Elewski, MD (2)
PMID 25913550, PMID 15389191, PMID 29448838, PMID 29776990, PMID 42694939, PMID 12810507, PMID 15787822, PMID 16882343, PMID 17092858, PMID 17373192, PMID 17500381, PMID 17853307, PMID 18047523, PMID 18380206, PMID 18856162, PMID 19043379, PMID 19423623, PMID 19740906, PMID 20098509, PMID 20098510, PMID 20124563, PMID 20399899, PMID 20406865, PMID 20428228, PMID 20857129, PMID 20858386, PMID 21173304, PMID 21284407, PMID 21455550, PMID 21551511, PMID 21797805, PMID 22035157, PMID 22127697, PMID 22463723, PMID 22751454, PMID 23204039, PMID 23468464, PMID 23981683, PMID 24120032, PMID 24369412, PMID 24682319, PMID 24861696, PMID 25087839, PMID 25231176, PMID 25434285, PMID 25535650, PMID 25606333, PMID 25645671, PMID 25881759, PMID 25946554
2016 (5), 2018 (3), 2023 (3), 2015 (2), 2019 (2), 2025 (2), 2005 (1), 2008 (1), 2014 (1), K23AR080043 (1), K23HL152013 (1)